Skip to main navigation Skip to search Skip to main content

In Vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases

  • Ryan K. Shields
  • , M. Hong Nguyen
  • , Ellen G. Press
  • , Liang Chen
  • , Barry N. Kreiswirth
  • , Cornelius J. Clancy
  • University of Pittsburgh
  • Rutgers - The State University of New Jersey, Newark
  • VA Medical Center

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Abstract

Ceftazidime-avibactam resistance is mediated by blaKPC-3 mutations, which restore carbapenem susceptibility. We subjected Klebsiella pneumoniae isolates with different blaKPC-3 mutations (n = 5) or wild-type blaKPC-3 (n = 2) to serial passages with meropenem. The meropenem MIC against each isolate increased. Mutations in the ompK36 porin gene evolved in 5 isolates. Among isolates with D179Y substitutions in KPC-3, blaKPC-3 mutations reverted to wild type, were replaced by new mutations, or were retained. Carbapenem treatment of ceftazidime-avibactam-resistant K. pneumoniae infections may select for carbapenem resistance.

Original languageEnglish
Article numbere00079
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number5
DOIs
StatePublished - May 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Carbapenem-resistant Enterobacteriaceae
  • Ceftazidime-avibactam resistance
  • Klebsiella pneumoniae carbapenemase
  • KPC mutations
  • Sequence type 258 Klebsiella pneumonia

Fingerprint

Dive into the research topics of 'In Vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases'. Together they form a unique fingerprint.

Cite this